Details of the Drug Reposition

General Information of This Drug (ID: DMDJRU1)

Drug Name
MM-121   DMDJRU1
Synonyms
SAR-256212; EGFR antibodies (cancer), Merrimack; ErbB antibodies (cancer), Merrimack; MM-1x1 program (cancer), Merrimack; EGFR family tyrosine kinase receptor inhibitor (intravenous formulation/monoclonal antibody, cancer/NSCLC), Merrimack Pharmaceuticals/sanofi-aventis; ErbB3 tyrosine kinase receptor modulator (intravenous formulation/monoclonal antibody, cancer/NSCLC), Merrimack Pharmaceuticals/sanofi-aventis

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-small-cell lung cancer DIS5Y6R9 2C25.Y Phase 2 [1]
Breast cancer DIS7DPX1 2C60-2C65 Phase 2 [2]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01447706) A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers. U.S. National Institutes of Health.